A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8+ T cell responses to rabies virus

Virology

Volumn 426, Issue 2, 2012, Pages 120-133

  Wanjalla, Celestine N ^a   Goldstein, Elizabeth F ^a,b   Wirblich, Christoph ^a   Schnell, Matthias J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytokine; GM CSF; Rabies virus; Viral immunity

Indexed keywords

GAG PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; RABIES VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOREGULATION; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RABIES; RABIES VIRUS; SPLEEN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN-PRESENTING CELLS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HIV INFECTIONS; HUMANS; MICE; MICE, INBRED BALB C; RABIES; RABIES VIRUS; SPLEEN;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; RABIES VIRUS;

EID: 84857789509     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.01.025     Document Type: Article

References (47)

1. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 1994, 68:6103-6110.
2. Brode S., Macary P.A. Cross-presentation: dendritic cells and macrophages bite off more than they can chew!. Immunology 2004, 112:345-351.
3. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., Restifo N.P., Zanovello P. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000, 96:3838-3846.
4. Bukreyev A., Belyakov I.M., Berzofsky J.A., Murphy B.R., Collins P.L. Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. J. Virol. 2001, 75:12128-12140.
5. Burgess A.W., Camakaris J., Metcalf D. Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. J. Biol. Chem. 1977, 252:1998-2003.
6. Carlsson T., Struve J. Granulocyte-macrophage colony-stimulating factor given as an adjuvant to persons not responding to hepatitis B vaccine. Infection 1997, 25:129.
7. Cenna J., Hunter M., Tan G.S., Papaneri A.B., Ribka E.P., Schnell M.J., Marx P.A., McGettigan J.P. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J. Infect. Dis. 2009, 200:1251-1260.
8. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:3539-3543.
9. Faul E.J., Wanjalla C.N., McGettigan J.P., Schnell M.J. Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. Virology 2008, 382:226-238.
10. Faul E.J., Aye P.P., Papaneri A.B., Pahar B., McGettigan J.P., Schiro F., Chervoneva I., Montefiori D.C., Lackner A.A., Schnell M.J. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine 2009, 28:299-308.
11. Gomme E.A., Faul E.J., Flomenberg P., McGettigan J.P., Schnell M.J. Characterization of a single-cycle rabies virus-based vaccine vector. J. Virol. 2010, 84:2820-2831.
12. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., Muramatsu S., Steinman R.M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 1992, 176:1693-1702.
13. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004, 5:987-995.
14. Jaffee E.M., Hruban R.H., Biedrzycki B., Laheru D., Schepers K., Sauter P.R., Goemann M., Coleman J., Grochow L., Donehower R.C., Lillemoe K.D., O'Reilly S., Abrams R.A., Pardoll D.M., Cameron J.L., Yeo C.J. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 2001, 19:145-156.
15. Janke M., Peeters B., de Leeuw O., Moorman R., Arnold A., Fournier P., Schirrmacher V. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther. 2007, 14:1639-1649.
16. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., Irwin C.E., Safrit J.T., Mittler J., Weinberger L., Kostrikis L.G., Zhang L., Perelson A.S., Ho D.D. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 1999, 189:991-998.
17. Kared H., Leforban B., Montandon R., Renand A., Layseca Espinosa E., Chatenoud L., Rosenstein Y., Schneider E., Dy M., Zavala F. Role of GM-CSF in tolerance induction by mobilized hematopoietic progenitors. Blood 2008, 112:2575-2578.
18. Kass E., Parker J., Schlom J., Greiner J.W. Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen-presenting cells in regional lymph nodes. Cytokine 2000, 12:960-971.
19. Kindt T.J., Goldsby Richard A., Osborne Barbara Anne, Kuby Janis Kuby Immunology 2007, Sara Tenney, New York. SIXTH EDITION ed.
20. Loudon P.T., Yager E.J., Lynch D.T., Narendran A., Stagnar C., Franchini A.M., Fuller J.T., White P.A., Nyuandi J., Wiley C.A., Murphey-Corb M., Fuller D.H. GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One 2010, 5:e11021.
21. Lu H., Xing Z., Brunham R.C. GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis. J. Immunol. 2002, 169:6324-6331.
22. Luiten R.M., Kueter E.W., Mooi W., Gallee M.P., Rankin E.M., Gerritsen W.R., Clift S.M., Nooijen W.J., Weder P., van de Kasteele W.F., Sein J., van den Berk P.C., Nieweg O.E., Berns A.M., Spits H., de Gast G.C. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J. Clin. Oncol. 2005, 23:8978-8991.
23. Mastrangelo M.J., Maguire H.C., Eisenlohr L.C., Laughlin C.E., Monken C.E., McCue P.A., Kovatich A.J., Lattime E.C. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1999, 6:409-422.
24. McGettigan J.P., Sarma S., Orenstein J.M., Pomerantz R.J., Schnell M.J. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J. Virol. 2001, 75:8724-8732.
25. McGettigan J.P., Naper K., Orenstein J., Koser M., McKenna P.M., Schnell M.J. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J. Virol. 2003, 77:10889-10899.
26. McGettigan J.P., Pomerantz R.J., Siler C.A., McKenna P.M., Foley H.D., Dietzschold B., Schnell M.J. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J. Virol. 2003, 77:237-244.
27. McGettigan J.P., Koser M.L., McKenna P.M., Smith M.E., Marvin J.M., Eisenlohr L.C., Dietzschold B., Schnell M.J. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. Virology 2006, 344:363-377.
28. Mebatsion T., Schnell M.J., Cox J.H., Finke S., Conzelmann K.K. Highly stable expression of a foreign gene from rabies virus vectors. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:7310-7314.
29. Metcalf D. Acute antigen-induced elevation of serum colony stimulating factor (CFS) levels. Immunology 1971, 21:427-436.
30. Metcalf D. Molecular control of granulocyte and macrophage production. Prog. Clin. Biol. Res. 1985, 191:323-337.
31. Metcalf D., Nicola N.A., Mifsud S., Di Rago L. Receptor clearance obscures the magnitude of granulocyte-macrophage colony-stimulating factor responses in mice to endotoxin or local infections. Blood 1999, 93:1579-1585.
32. Parmiani G., Castelli C., Pilla L., Santinami M., Colombo M.P., Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 2007, 18:226-232.
33. Plesa G., McKenna P.M., Schnell M.J., Eisenlohr L.C. Immunogenicity of cytopathic and noncytopathic viral vectors. J. Virol. 2006, 80:6259-6266.
34. Ramsburg E., Publicover J., Buonocore L., Poholek A., Robek M., Palin A., Rose J.K. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals. J. Virol. 2005, 79:15043-15053.
35. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
36. Schnell M.J., McGettigan J.P., Wirblich C., Papaneri A. The cell biology of rabies virus: using stealth to reach the brain. Nat. Rev. Microbiol. 2010, 8:51-61.
37. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004, 64:6337-6343.
38. Stanley E., Lieschke G.J., Grail D., Metcalf D., Hodgson G., Gall J.A., Maher D.W., Cebon J., Sinickas V., Dunn A.R. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:5592-5596.
39. Steinman R. Dendritic cells: understanding immunogenicity. Eur. J. Immunol. 2007, 37:S53-S60.
40. Steinman R.M., Pope M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 2002, 109:1519-1526.
41. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003, 21:685-711.
42. Vasu C., Dogan R.N., Holterman M.J., Prabhakar B.S. Selective induction of dendritic cells using granulocyte macrophage-colony stimulating factor, but not fms-like tyrosine kinase receptor 3-ligand, activates thyroglobulin-specific CD4+/CD25+ T cells and suppresses experimental autoimmune thyroiditis. J. Immunol. 2003, 170:5511-5522.
43. Wanjalla C.N., Faul E.J., Gomme E.A., Schnell M.J. Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity. Vaccine 2010, 29:130-140.
44. Wen Y., Wang H., Wu H., Yang F., Tripp R.A., Hogan R.J., Fu Z.F. Rabies virus expressing dendritic cell-activating molecules enhances the innate and adaptive immune response to vaccination. J. Virol. 2010, 85:1634-1644.
45. Wirblich C., Schnell M.J. Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV. J. Virol. 2011, 85:697-704.
46. Yoon H.A., Aleyas A.G., George J.A., Park S.O., Han Y.W., Lee J.H., Cho J.G., Eo S.K. Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses. Microbiol. Immunol. 2006, 50:83-92.
47. Zhang S.N., Choi I.K., Huang J.H., Yoo J.Y., Choi K.J., Yun C.O. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol. Ther. 2011, 19(8):1558-1568.